• Medicine
  • Published 2010

Clinical overview of trimetazidine (Vastarel MR) in patients with heart failure

@inproceedings{Uuetoa2010ClinicalOO,
  title={Clinical overview of trimetazidine (Vastarel MR) in patients with heart failure},
  author={Tiina Uuetoa},
  year={2010}
}
Myocardial energy metabolism may be normal in the early stages of heart failure but, as failure progresses, mitochondrial oxidative metabolism is reduced and glycolysis is increased, with downregulation of glucose oxidation. Reducing free fatty acid oxidation and a concomitant increase in glucose oxidation improve cardiac contraction and slow the progression of left ventricular failure. Trimetazidine (TMZ) acts as a partial inhibitor of fatty acid oxidation and in turn stimulates glucose… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy

  • G Fragasso, PM Piatti, L Monti
  • Am Heart J. 2003;146:E18
  • 2003
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium

VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Effects of Vastarel MR on brain natriuretic peptide and cardiac troponin concentrations

  • P. Di Napoli
  • Heart Metab
  • 2009
VIEW 1 EXCERPT

Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy

  • P Di Napoli, P Di Giovanni, MA Gaeta, G D’Apolito, A. Barsotti
  • Am Heart J. 2007;154:602.e1–602.e5
  • 2007
VIEW 2 EXCERPTS